Theralase presents Phase 1b NMIBC study at AUA conference

theralase_logos_TEAL-for-WEBSITE.png

Theralase Technologies’ (TSXV:TLT; OTCQB:TLTFF) presented its Phase 1b clinical study of its anti-cancer therapy (ACT) for non-muscle invasive bladder cancer (NMIBC) at the American Urological Association conference in Chicago.

The presentation by Lother Lilge, Prof. of medical biophysics at the University of Toronto, senior scientist at University Health Network and a member of Theralase’s medical and SAB, focused on the technology and science used by the company to successfully complete the Phase 1b study, specifically the laser light emission and laser light detection utilized to safely and effectively destroy NMIBC.

Shawn Shirazi, CEO of Theralase’s drug division, said human bladders come in a variety of shapes and sizes and the company’s ACT technology is able to automatically adjust the laser light delivered to the bladder wall in response to these differences through real-time laser light detection. The advanced ACT technology resulted in the study demonstrating a 66% complete response up to 360 days post treatment.

The company’s Phase 2 NMIBC study has received Health Canada clinical trial authorization and investigational testing authorization, as well as University Health Network research ethics board approval.

Mr. Shirazi said today’s conventional therapies for NMIBC patients remain primarily palliative in nature and not curative. “Theralase is firmly committed to developing the next stand of care for NMIBC,” he added.

Michelle Carr